Opdivo-Yervoy
BMS Withdraws Opdivo Indication for HCC Monotherapy
In consultation with the FDA, Bristol Myers Squibb (BMS) has voluntarily withdrawn from the U.S. market the ...
JULY 26, 2021
FDA Grants Mesothelioma Indication to Opdivo Plus Yervoy
The FDA approved a new indication for the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy), both ...
OCTOBER 5, 2020
FDA Approves Two Checkpoint Inhibitor Regimens for First-Line Metastatic NSCLC Treatment
The regimens were approved as first-line treatment for patients with metastatic NSCLC whose tumors express ...
MAY 20, 2020
Load more